Teva reaches proposed $4.35 bln settlement of U.S. opioid lawsuits | Reuters
Teva stock downgraded to neutral by UBS on heels of $85 million opioid settlement - MarketWatch
Suffering from missteps, drugmaker Teva struggles to heal own ills | The Times of Israel
$4.4 Billion Opioid Settlement Gives Teva Stock a Boost | Barron's
Jennifer Bryan - Head of Commercial Training & Development - Teva Pharmaceuticals | LinkedIn
Teva shares hit 19-year low after opioid settlement, analyst downgrades | Fierce Pharma
$4.4 Billion Opioid Settlement Gives Teva Stock a Boost | Barron's
Teva cut to Sell at UBS citing uncertainty over leadership transition (NYSE: TEVA) | Seeking Alpha
Teva stock drops on guidance, manufacturing problems - MarketWatch
Teva Becomes First Pharmaceutical Company to Execute Sustainability-Linked Bond Tied to Both Climate and Access to Medicine Targets
Teva Pharmaceutical Will Pay Over $4 Billion in Opioid Settlement - Bloomberg
Teva Pharmaceutical Industries Stock Jumps on a Rare Bullish View | Barron's
Teva boosted as FDA delays generic Copaxone - Globes
Teva Prepared to Fight Charges in Generics Probe If Talks Fail - Bloomberg
Teva, AbbVie finalize $6.6 billion U.S. opioid settlements | Reuters
Teva says vaccine makers have not taken its offer to help produce jabs | Financial Times
Teva jumps after Wall Street upgrades, analysts say stock 'too cheap to ignore'
Teva Pharmaceuticals Archives - Drug Discovery and Development
Teva Tries to Put an End to the Opioid Wars - WSJ
Teva hires ex-Novartis executive to succeed CEO Schultz | Reuters
Quest upgraded while Teva downgraded at UBS, and VectiveBio scores two new buy initiations in today's analyst action - ADVFN
Teva Plummets on Downgrade Following $85M Opioid Settlement - TheStreet
Teva Pharmaceuticals is found liable in the opioid crisis : NPR
